Chronic Hepatitis B (CHB) epidemiology report gives a thorough understanding of the Chronic Hepatitis B (CHB) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

Chronic Hepatitis B (CHB) Epidemiology Forecast |Chronic Hepatitis B Virus (CHB) prevalent population

DelveInsight&#39;s &quot;Chronic Hepatitis B (CHB) - Epidemiology Forecast-2032&quot; report delivers an in-depth understanding of the Chronic Hepatitis B (CHB), historical and forecasted epidemiology as well as the Chronic Hepatitis B (CHB) trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

<h2>Geography Covered</h2>

<ul>
	<li>The United States</li>
	<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li>
	<li>Japan</li>
</ul>

Study Period: 2019-2032

<h2>Chronic Hepatitis B (CHB) Understanding</h2>

The DelveInsight&rsquo;s Chronic Hepatitis B (CHB) epidemiology report gives a thorough understanding of chronic hepatitis B by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Chronic Hepatitis B (CHB) has been described as &ldquo;a heterogeneous disease with markedly variable levels of viral replication and liver disease activity&rdquo;. It is characterized by liver injury mediated by a T-cell immune response targeting hepatocytes that express viral antigens. It can lead to the development of chronic hepatitis, cirrhosis, and HCC. As well as in HCV, chronic HBV infection is associated with age, cell cycle arrest, and CS.

&nbsp;

Chronic hepatitis B is usually asymptomatic. The most common symptom is fatigue, but sleep disorders, difficulty concentrating, and upper right quadrant pain are often observed. Chronic hepatitis B infection lasts six months or longer. It lingers because the immune system can&#39;t fight off the infection. Chronic hepatitis B infection may last a lifetime, possibly leading to serious illnesses such as cirrhosis and liver cancer. The risk of developing a chronic hepatitis B infection is also directly related to the age at which one first becomes exposed to the hepatitis B virus.

&nbsp;

Diagnosis

Chronic infection may go undetected for decades until a person becomes seriously ill from liver disease. If signs of liver damage are present, the doctor will perform several tests to diagnose chronic hepatitis B, including blood tests to detect signs of hepatitis B virus in the body and liver ultrasound and biopsy to determine the amount of liver damage. Doctors sometimes also test certain healthy people for hepatitis B infection because the virus can damage the liver before causing signs and symptoms.

<h2>Chronic Hepatitis B (CHB) Epidemiology</h2>

The epidemiology section provides insights into the historical and current chronic hepatitis B patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

&nbsp;

Key Findings

The disease epidemiology covered in the report provides a historical as well as forecasted chronic hepatitis B epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

&nbsp;

In the year 2021, the total diagnosed prevalent cases of chronic hepatitis B were 2,165,851 cases in the 7MM which are expected to grow during the study period, i.e., 2019&ndash;2032.

&nbsp;

The disease epidemiology covered in the report provides historical as well as forecasted chronic hepatitis B epidemiology [segmented as Prevalent population Cases of CHB, Diagnosed prevalent cases of CHB, Gender-specific cases of CHB, Age-Specific cases of CHB, Type-specific cases of CHB, and Total Treated Cases of CHB] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

<h2>Country Wise- Chronic Hepatitis B (CHB) Epidemiology</h2>

The epidemiology segment also provides the chronic hepatitis B epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

<h2>KOL- Views</h2>

To keep up with the current chronic hepatitis B patient pool and forecasted trend, we take KOLs and SMEs &#39; opinions working in the chronic hepatitis B domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

<h2>Scope of the Report</h2>

<ul>
	<li>The report covers the descriptive overview of Chronic Hepatitis B (CHB), explaining its causes, symptoms, pathophysiology, and genetic basis.</li>
	<li>The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.</li>
	<li>The report assesses the disease risk and burden and highlights the unmet needs of Chronic Hepatitis B (CHB).</li>
	<li>The report helps to recognize the growth opportunities in the 7MM concerning the patient population.</li>
	<li>The report provides the segmentation of the disease epidemiology for 7MM by Prevalent population Cases of CHB, Diagnosed prevalent cases of CHB, Gender-specific cases of CHB, Age-Specific cases of CHB, Type-specific cases of CHB, and Total Treated Cases of CHB.</li>
</ul>

<h2>Report Highlights</h2>

<ul>
	<li>The companies and academics are working to assess challenges and seek opportunities that could influence chronic hepatitis B R&amp;D. The therapies under development are focused on novel approaches to treat/improve the disease condition&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
	<li>A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for chronic hepatitis B</li>
	<li>Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities</li>
</ul>

<h2>Chronic Hepatitis B (CHB) Report Key Strengths</h2>

<ul>
	<li>11 Years Forecast</li>
	<li>7MM Coverage</li>
	<li>Chronic Hepatitis B (CHB)&nbsp; Epidemiology Segmentation</li>
</ul>

<h2>Key Questions</h2>

Epidemiology Insights:

<ul>
	<li>What are the disease risk, burden, and regional/ethnic differences of chronic hepatitis B?</li>
	<li>What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
	<li>What is the historical chronic hepatitis B patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
	<li>What would be the forecasted patient pool of chronic hepatitis B in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
	<li>Where will be the growth opportunities in the 7MM concerning the patient population about Chronic Hepatitis B?</li>
	<li>Out of all 7MM countries, which country would have the highest prevalent population of Chronic Hepatitis B during the forecast period (2019-2032)?</li>
	<li>At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?</li>
</ul>

<h2>Reasons to buy</h2>

<ul>
	<li>The report will help in developing business strategies by understanding trends shaping and driving the Chronic Hepatitis B (CHB) Disease market</li>
	<li>To understand the future market competition in the Chronic Hepatitis B (CHB) Disease market and Insightful review of the key market drivers and barriers</li>
	<li>Organize sales and marketing efforts by identifying the best opportunities for Chronic Hepatitis B (CHB)&nbsp; Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan</li>
	<li>Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors</li>
	<li>Organize sales and marketing efforts by identifying the best opportunities for the Chronic Hepatitis B (CHB)&nbsp; Disease market</li>
	<li>To understand the future market competition in the Chronic Hepatitis B (CHB) Disease market</li>
</ul>

1. Key Insights

2. Report Introduction

3. Chronic Hepatitis B Market Overview at a Glance

3.1. Market Share (%) Distribution of Chronic Hepatitis B in 2019

3.2. Market Share (%) Distribution of Chronic Hepatitis B in 2032

4. Executive Summary of Chronic Hepatitis B (CHB)

4.1. Key events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Acute and Chronic Hepatitis B Infection

6.3. Signs and Symptoms

6.4. Risk Factors and Causes

6.5. Transmission of Hepatitis B Virus

6.6. Pathophysiology

6.7. Stages of HBV Infection

6.8. Complications of Hepatitis B Virus Infection

7. Diagnosis of Hepatitis B Infection

7.1. Screening Tests for Hepatitis B Infection

7.2. Liver Related Blood Tests

7.3. Tests to Diagnose Hepatitis B Virus

7.3.1. Medical History and Physical exam

7.3.2. Imaging tests

7.3.3. MRI and CT Scans

7.4. Liver Biopsy for Hepatitis B Virus

7.5. Diagnostic Guidelines of Hepatitis B Infection

7.5.1. World Health Organization (WHO) Diagnostic Guidelines

7.5.2. American Association for the Study of Liver Diseases (AASLD) Diagnostic Guidelines

7.5.3. European Association for the Study of the Liver (EASL) Diagnostic Guidelines

7.6. Prevention of Hepatitis B Infection

8. Current Treatment Practices

8.1. Treatment Algorithm

8.2. Treatment Guidelines

8.2.1. AASLD 2018 Practice Guidelines for Treatment of Chronic Hepatitis

8.2.2. European Association for the Study of the Liver (EASL) 2017 Clinical Practice Guidelines for Hepatitis

8.2.3. Hepatitis B management: Guidance for the Primary Care Provider

8.2.4. World Health Organization Guidelines for the management and treatment of CHB

8.2.5. Japan Society of Hepatology for the Management of Hepatitis B Virus Infection (2014)

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Epidemiology of Chronic Hepatitis B

9.3. Epidemiology Scenario

9.3.1. Prevalent Population of Chronic Hepatitis B

9.3.2. Diagnosed Prevalent Cases of Chronic Hepatitis B

9.3.3. Gender-specific Cases of Chronic Hepatitis B

9.3.4. Age-specific Cases of Chronic Hepatitis B

9.3.5. Type-specific Cases of Chronic Hepatitis B

9.3.6. Total Treated Cases of Chronic Hepatitis B

10. Appendix

10.1. Bibliography

10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

DelveInsight's "Chronic Hepatitis B (CHB) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Hepatitis B (CHB) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Hepatitis B (CHB) - Epidemiology Forecast - 2032

DelveInsight's Chronic Hepatitis B (CHB) - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology..